-
1
-
-
0033545541
-
Rising incidence of hepatocellular carcinoma in the United States
-
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999; 340: 745-750.
-
(1999)
N. Engl. J. Med.
, vol.340
, pp. 745-750
-
-
El-Serag, H.B.1
Mason, A.C.2
-
4
-
-
79952231921
-
Management of hepatocellular carcinoma: an update
-
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
-
(2011)
Hepatology
, vol.53
, pp. 1020-1022
-
-
Bruix, J.1
Sherman, M.2
-
5
-
-
84871830149
-
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage
-
Kim do Y, Han KH. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. Dig. Dis. 2012; 30: 598-602.
-
(2012)
Dig. Dis.
, vol.30
, pp. 598-602
-
-
Kim do, Y.1
Han, K.H.2
-
6
-
-
52049096005
-
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis
-
Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
-
(2008)
Cancer
, vol.113
, pp. 995-1003
-
-
Han, K.H.1
Seong, J.2
Kim, J.K.3
Ahn, S.H.4
Lee do, Y.5
Chon, C.Y.6
-
7
-
-
34250888086
-
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma
-
Park JY, Ahn SH, Yoon YJ etal. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
-
(2007)
Cancer
, vol.110
, pp. 129-137
-
-
Park, J.Y.1
Ahn, S.H.2
Yoon, Y.J.3
-
8
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
Wilhelm SM, Carter C, Tang L etal. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-7109.
-
(2004)
Cancer Res.
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
9
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
-
(2009)
Lancet Oncol.
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
10
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
11
-
-
84864794559
-
Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib
-
Kawaoka T, Aikata H, Murakami E etal. Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012; 83: 192-200.
-
(2012)
Oncology
, vol.83
, pp. 192-200
-
-
Kawaoka, T.1
Aikata, H.2
Murakami, E.3
-
12
-
-
84872771082
-
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma
-
Lee JH, Chung YH, Kim JA etal. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013; 119: 136-142.
-
(2013)
Cancer
, vol.119
, pp. 136-142
-
-
Lee, J.H.1
Chung, Y.H.2
Kim, J.A.3
-
13
-
-
84862776834
-
Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma
-
Kim JE, Ryoo BY, Ryu MH etal. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 2012; 82: 119-125.
-
(2012)
Oncology
, vol.82
, pp. 119-125
-
-
Kim, J.E.1
Ryoo, B.Y.2
Ryu, M.H.3
-
14
-
-
84868605784
-
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma
-
Nakano M, Tanaka M, Kuromatsu R etal. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology 2013; 84: 108-114.
-
(2013)
Oncology
, vol.84
, pp. 108-114
-
-
Nakano, M.1
Tanaka, M.2
Kuromatsu, R.3
-
15
-
-
75349086029
-
Practice guidelines for management of hepatocellular carcinoma 2009
-
Korean Liver Cancer Study Group and National Cancer Center.
-
Korean Liver Cancer Study Group and National Cancer Center. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009; 15: 391-423.
-
(2009)
Korean J. Hepatol.
, vol.15
, pp. 391-423
-
-
-
16
-
-
84855174099
-
Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion
-
Chun YH, Ahn SH, Park JY etal. Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. Anticancer Res. 2011; 31: 4641-4646.
-
(2011)
Anticancer Res.
, vol.31
, pp. 4641-4646
-
-
Chun, Y.H.1
Ahn, S.H.2
Park, J.Y.3
-
17
-
-
54949157603
-
Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors
-
Kim SU, Kim Y, Park JY etal. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J. Cancer Res. Clin. Oncol. 2008; 134: 1377-1384.
-
(2008)
J. Cancer Res. Clin. Oncol.
, vol.134
, pp. 1377-1384
-
-
Kim, S.U.1
Kim, Y.2
Park, J.Y.3
-
18
-
-
75649116842
-
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
-
Vincenzi B, Santini D, Russo A etal. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92.
-
(2010)
Oncologist
, vol.15
, pp. 85-92
-
-
Vincenzi, B.1
Santini, D.2
Russo, A.3
-
19
-
-
79959421984
-
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models
-
Baek KK, Kim JH, Uhm JE etal. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011; 80: 167-174.
-
(2011)
Oncology
, vol.80
, pp. 167-174
-
-
Baek, K.K.1
Kim, J.H.2
Uhm, J.E.3
-
20
-
-
67651095716
-
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
-
Worns MA, Weinmann A, Pfingst K etal. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 2009; 43: 489-495.
-
(2009)
J. Clin. Gastroenterol.
, vol.43
, pp. 489-495
-
-
Worns, M.A.1
Weinmann, A.2
Pfingst, K.3
-
21
-
-
33749017926
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
-
Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006; 24: 4293-4300.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 4293-4300
-
-
Abou-Alfa, G.K.1
Schwartz, L.2
Ricci, S.3
-
22
-
-
84862737988
-
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study
-
Lencioni R, Kudo M, Ye SL etal. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int. J. Clin. Pract. 2012; 66: 675-683.
-
(2012)
Int. J. Clin. Pract.
, vol.66
, pp. 675-683
-
-
Lencioni, R.1
Kudo, M.2
Ye, S.L.3
-
23
-
-
84867871965
-
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits
-
Chiu J, Tang YF, Yao TJ etal. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012; 118: 5293-5301.
-
(2012)
Cancer
, vol.118
, pp. 5293-5301
-
-
Chiu, J.1
Tang, Y.F.2
Yao, T.J.3
-
24
-
-
45749152254
-
Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients
-
Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 2008; 9: 267-274.
-
(2008)
JOP
, vol.9
, pp. 267-274
-
-
Saif, M.W.1
Merikas, I.2
Tsimboukis, S.3
Syrigos, K.4
-
25
-
-
84884288905
-
The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
-
Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target. Oncol. 2013; 8: 173-181.
-
(2013)
Target. Oncol.
, vol.8
, pp. 173-181
-
-
Petrelli, F.1
Borgonovo, K.2
Barni, S.3
-
26
-
-
80955142670
-
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors
-
Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur. J. Gastroenterol. Hepatol. 2011; 23: 1233-1238.
-
(2011)
Eur. J. Gastroenterol. Hepatol.
, vol.23
, pp. 1233-1238
-
-
Song, T.1
Zhang, W.2
Wu, Q.3
Kong, D.4
Ma, W.5
-
27
-
-
84867464777
-
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma
-
Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 2013; 84: 6-13.
-
(2013)
Oncology
, vol.84
, pp. 6-13
-
-
Koschny, R.1
Gotthardt, D.2
Koehler, C.3
Jaeger, D.4
Stremmel, W.5
Ganten, T.M.6
-
28
-
-
84859722049
-
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis
-
Memon K, Kulik L, Lewandowski RJ etal. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J. Hepatol. 2012; 56: 1112-1120.
-
(2012)
J. Hepatol.
, vol.56
, pp. 1112-1120
-
-
Memon, K.1
Kulik, L.2
Lewandowski, R.J.3
-
29
-
-
84877011264
-
Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
-
Nakazawa T, Hidaka H, Takada J etal. Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur. J. Gastroenterol. Hepatol. 2013; 25: 683-689.
-
(2013)
Eur. J. Gastroenterol. Hepatol.
, vol.25
, pp. 683-689
-
-
Nakazawa, T.1
Hidaka, H.2
Takada, J.3
-
30
-
-
57349090407
-
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
-
Hoshida Y, Villanueva A, Kobayashi M etal. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 1995-2004.
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 1995-2004
-
-
Hoshida, Y.1
Villanueva, A.2
Kobayashi, M.3
-
31
-
-
84859393351
-
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival
-
957-66 e12
-
Roessler S, Long EL, Budhu A etal. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012; 142: 957-66 e12.
-
(2012)
Gastroenterology
, vol.142
-
-
Roessler, S.1
Long, E.L.2
Budhu, A.3
|